

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
(071838.0142)

Serial No.  
10/699,035

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)**

Applicants  
Bateman et al.

Filing Date  
October 31, 2003

Group Art Unit  
1644

**U.S. PATENT DOCUMENTS**

*Ex am. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENT**

Document No.	Date	Name	Class	SubClass	Translator Yes No

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

		Arikawa-Hirasawa et al., "Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. <i>Nat. Genet.</i> 2001 Apr;27(4):431-4.
		Arikawa-Hirasawa et al., "Perlecan is essential for cartilage and cephalic development," <i>Nat Genet.</i> 1999 Nov;23(3):354-8.

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants:	Bateman <i>et al.</i>	Conf. No.:	3842
Serial No.:	10/699,035	Examiner:	Haddad, M.M.
Filed:	October 31, 2003	Group Art Unit:	1644
For:	A MOLECULAR MARKER		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

November 2, 2006

**Mail Stop Amendments**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 and respectfully requests that the listed documents be considered by the Examiner and made of record in the above-captioned application.

This Supplemental Information Disclosure Statement is being filed together with a Supplemental Response to a March 31, 2006 Office Action. Copies of the listed documents are attached as Exhibits 1-2 that accompany the Supplemental Response.

This Statement is being filed after the mailing date of the first action on the merits but before the date of any final action, and is accompanied by authorization in the Fee Transmittal, to charge the fee of \$180 pursuant to 37 C.F.R. § 1.17(p) to a deposit account. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by initializing the PTO-1449 form and returning a copy of the initialized form with the next office communication.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior

art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants do not believe that any additional fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Director is hereby authorized, in the accompanying Transmittal and Fee Transmittal to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377.

Respectfully submitted,

  
\_\_\_\_\_  
Kimberley A. Gavin, Reg. No. 51,723  
Agent for Applicants

Baker Botts L.L.P  
Customer No. **21003**  
30 Rockefeller Plaza  
New York, NY 10012-4498  
212-408-2500